Uliledlimab (anti-CD73) is a potent against CD73 humanized monoclonal antibody. Uliledlimab (anti-CD73) inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab (anti-CD73) can be used in research of cancer. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
26.6 kDa (Light Chain) & 53.7 kDa (Heavy Chain), under reducing conditions; 197.8 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Purity
>95% (SDS-PAGE&SEC)
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2378407-27-1
Images
Uliledlimab (anti-CD73) (Ab182937) - Flow Cytometry Flow Cytometry analysis of A431 cells labelling CD73 (red) with Uliledlimab (anti-CD73) (Ab182937). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Uliledlimab (anti-CD73) (Ab182937) - ELISA Immobilized human CD73-his tag at 2.0 μg/mL can bind Uliledlimab (anti-CD73) (Ab182937) with the EC50 is 58.13 μg/mL.
Uliledlimab (anti-CD73) (Ab182937) - SEC The purity of Uliledlimab (anti-CD73) (Ab182937) is more than 95% verified by HPLC.